Merus/$MRUS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Ticker

$MRUS
Primary listing

Industry

Biotechnology

Employees

291

Merus Metrics

BasicAdvanced
$5B
-
-$4.14
1.00
-

What the Analysts think about Merus

Analyst ratings (Buy, Hold, Sell) for Merus stock.

Bulls say / Bears say

Merus has established strategic collaborations with major pharmaceutical companies, including Gilead Sciences and Eli Lilly, enhancing its growth prospects. (tipranks.com)
The company reported a substantial increase in cash and cash equivalents, reaching $433 million by the end of Q3 2024, up from $204 million at the end of 2023, providing a strong financial foundation for future operations. (tipranks.com)
Analysts have maintained a 'buy' rating on Merus, with an average price target of $85.64, indicating confidence in the company's future performance. (etfdailynews.com)
Merus reported a net loss of $99.9 million for Q3 2024, a significant increase from $23 million in the same period the previous year, primarily due to heightened research and administrative expenses. (tipranks.com)
KBC Group NV significantly reduced its holdings in Merus by 94.9% during the first quarter of 2025, potentially indicating decreased confidence from institutional investors. (marketbeat.com)
The company's general and administrative expenses increased by $23 million in 2024 compared to 2023, driven by higher personnel-related costs and consultancy expenses, which could impact profitability. (itiger.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Merus Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merus Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRUS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs